Adjuvant treatment of postmenopausal women w/ oestrogen-receptor +ve invasive early breast cancer, following 2-3 yr of initial adjuvant tamoxifen therapy. Advanced breast cancer in women w/ natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.
Adult & elderly 25 mg tab once a day. Early breast cancer Continue treatment until completion of 5 yr of combined sequential adjuvant hormonal therapy (tamoxifen followed by exemestane), or earlier if tumour relapse occurs. Advanced breast cancer Continue treatment until tumour progression is evident.
Should not be administered to women w/ premenopausal endocrine status. Assess of LH, FSH & oestradiol levels. +ve doping control test result. Reduction in bone mineral density & increased fracture rate. Assess bone mineral density & increased fracture rate. May affect ability to drive or operate machinery. Hepatic & renal impairment. Not recommended in childn.
Sign Out
